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Highlights 
 
 
 CPX-351 uptake is not dependant on human equilibrative 
nucleoside transporter 1 (hENT1) expression. 
 Fludarabine can potentiate in vitro ara-CTP generation and 
cytotoxicity from CPX-351 in leukaemic cell lines. 
 Pre-treatment of ex vivo AML blasts with fludarabine potentiates ara-
CTP production from CPX-351. 
 
 
Abstract 
 
 
CPX-351, a liposomal formulation co-encapsulating cytarabine and 
daunorubicin (DNR) in a synergistic 5:1 molar ratio, has shown favourable 
response in newly diagnosed elderly high-risk AML. This study assessed 
intracellular ara-CTP levels following in vitro exposure of human 
immortalised leukaemic cell lines and primary AML blasts to CPX-351, and 
investigated fludarabine potentiation of intracellular ara-CTP formation 
from CPX-351. Comparison of intracellular handling of CPX-351 to cytarabine 
in HL-60 cells indicated slower conversion to ara-CTP for CPX-351, but 
equivalent cytotoxicity to cytarabine and combined DNR/cytarabine (DA) at 
48 hours, mostly likely reflecting the need for intracellular liposome 
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processing to release encapsulated drugs. Further assessment 
demonstrated cytotoxicity of CPX-351 to be superior to DA at 48 and 72 
hours in cytarabine-resistant THP-1 cells (p<0.001), and this effect could not 
be inhibited upon blockade of human equilibrative nucleoside transporter 
(hENT) function with dipyridamole. Assessment of Flu-CPX in primary blasts 
from presentation AML patients (n=5) demonstrated a more rapid and 
pronounced potentiation of ara-CTP from CPX-351 than in immortalised cell 
lines, with 4/5 patients showing significant increases in ara-CTP, notably for 
those that went on to fail induction and relapse treatment in vivo (n=3). This 
suggests a favourable impact on patient outcome from Flu-CPX. 
 
Abbreviations: ara-C, cytosine arabinoside/cytarabine; DNR, daunorubicin, 
ara-CTP, cytosine arabinoside triphosphate; dCTP, deoxycytidine 
triphosphate; dCK, deoxycytidine kinase; hENT, human equilibrative 
nucleoside transporter; DPM, dipyridamole; CDA, cytidine deaminase; FLT3-
ITD, FMS-like tyrosine kinase 3 internal tandem duplication; NPM1, 
nucleophosmin 1; G-CSF, granulocyte colony stimulating factor; FLAG-Ida, 
fludarabine, ara-C, G-CSF, idarubicin; FBS, foetal bovine serum; SI%, 
sensitivity index. 
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Introduction 
 
 
Cytarabine (ara-C) is a well-established agent widely used for treating AML. 
Conventionally, it is combined with anthracyclines for treating newly 
diagnosed Acute Myeloid Leukaemia (AML). At higher doses it is combined 
with the purine analogue fludarabine plus idarubicin and G-CSF (FLAG-Ida) 
for the treatment of relapsed or refractory AML. Fludarabine is known to 
potentiate intracellular accumulation of the active cytotoxic metabolite ara-
CTP from ara-C via inhibition of ribonucleotide reductase and the normal 
formation of endogenous dCTP (Gandhi et al., 1993), and removal of the 
inhibition of deoxycytidine kinase (dCK) by dCTP (Liliemark and Plunkett, 
1986; Datta et al., 1989). 
CPX-351 is a proprietary liposomal formulation of ara-C and daunorubicin 
(DNR) encapsulated at a synergistic 5:1 molar ratio found to markedly 
enhance efficacy in preclinical leukaemia models (Tardi et al., 2009; Lim et 
al., 2010).  CPX-351 exhibits an improved therapeutic index compared to 
conventional DA therapy in newly diagnosed elderly AML patients (Lancet et 
al., 2014) as well as in patients with relapsed or resistant to DA therapy 
(Feldman et al., 2011, Cortes et al., 2015). The rationale behind the 
improvements observed for CPX-351 lies in the altered drug distribution and 
metabolism (Feldman et al., 2012) that leads to prolonged circulation time 
and elevated concentrations within the blood (Tardi et al., 2009), as well as 
concentration within the bone marrow (Lim et al., 2010) and a selectivity for 
leukaemic progenitor cells over normal haemopoietic cells (Kim et al., 2011). 
However, the intracellular kinetics of CPX-351 and metabolism of free 
intracellular ara-C and DNR resulting from CPX-351 are yet to be determined. 
In a Phase III trial, CPX was compared to 7+3 ara-C/DNR in newly diagnosed 
elderly high risk (secondary) AML patients, and showed superior event free 
survival and overall survival (Brunetti et al., 2017) supporting the use of CPX-
351 in these patients which led to its recent approval by FDA. In addition, a 
recent study evaluating ex vivo blasts from sub-populations of AML patients 
has revealed the potential advantage of treating FLT3-ITD positive AML cells 
with CPX-351 (Gordon et al., 2017). These and other positive results have led 
to planned evaluation of CPX-351 on the UK National Cancer Research 
Institute (NCRI) Phase 3 AML 18 trial for elderly patients with AML and 
myelodysplastic syndrome (MDS). CPX-351 is also being evaluated versus 
FLAG-Ida in the UK NCRI AML 19 trial for younger patients with high-risk AML 
(known adverse cytogenetics). To explore the possibility of exploiting the 
same benefits of combination fludarabine therapy used in the FLAG-Ida 
regimen, we evaluated Flu-CPX versus CPX-351 in a range of immortalised 
cell lines and primary blasts from patients with refractory disease. 
Intracellular ara-CTP was assessed using biosensor HA1, which has been 
shown as equivalent to assessment by high performance liquid 
chromatography (HPLC) (R2 0.972, p=0.0028), with a lower limit of detection 
(Anderson et al., 2013) and using one fifth the requirement of HPLC for 
patient blasts (Yamauchi et al., 2009). The effect of human equilibrative 
nucleoside transporter (hENT) blockade on uptake and metabolism of CPX-
351 was assessed in the cytarabine-resistant THP-1 cell line, as down-
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regulation of hENT1 has previously been implicated in resistance to 
cytarabine treatment (Macanas-Pirard et al., 2017). 
Methods 
Preparation of biosensor 
An overnight culture of E. coli HA1 was cultured in RPMI-1640 medium 
(Invitrogen) supplemented with foetal bovine serum (FBS, Sigma-Aldrich, 
UK) (10%) and L-glutamine (2 mM, Invitrogen, UK) and the optical density 
(OD 600 nm) adjusted to OD 1.0 in fresh RPMI 1640 medium (colourless, 
unsupplemented) pre-warmed to 37C. The OD 1.0 culture was incubated 
for 30 minutes at 37°C in an orbital shaker at 200 rpm prior to use. 
Maintenance and propagation of cell lines 
Cell lines HL-60, KG-1a, K562 and THP-1 were grown in RPMI 1640 
supplemented with FBS (10%) and L-glutamine (2 mM) in 75 cm2 tissue 
culture flasks (Corning) at 37°C in an atmosphere enriched with 5% CO2. Cells 
were sub-cultured 1:5 into fresh supplemented RPMI 1640 medium twice 
weekly.  
Optimisation of CPX-351 dosing interval in HL-60 cells 
Viable immortalised HL-60 cells were enumerated using Trypan Blue staining 
(Sigma-Aldrich) and an Improved Neubauer haemocytometer, harvested by 
centrifugation at 300 x g for 5 minutes, and re-suspended to a density of 2 x 
106 cells/mL in RPMI 1640 minimal medium (colourless, unsupplemented). 
Aliquots (2mL) were dosed with DA (DNR 5 µM, ara-C 25 µM) or CPX-351 (25 
µM), and incubated for 1, 2 or 4 hours at 37°C in an atmosphere enriched 
with 5% CO2. The concentration of CPX-351 was calculated to produce the 
molar equivalents of standard dose ara-C. The concentrations of DNR and 
ara-C were calculated from clinically relevant doses based on dosing a 70 kg 
individual (surface area 1.73 m2) with standard dose DA. 
Preparation of cell lysate 
After treatment cells were centrifuged at 300 x g for 5 minutes, washed in 4 
mL RPMI 1640 medium (unsupplemented, minus phenol red) and re-
suspended in 2 mL RPMI 1640 medium (unsupplemented, minus phenol red) 
containing saponin (0.1%) and EDTA (1.75 mM) as per Alloush et al. (2010). 
Cells were vortexed, and cell debris removed from cell lysate by 
centrifugation at 2800 xg for 5 minutes. Cell lysates were produced and used 
immediately or stored at -20°C and thawed to room temperature before use. 
Assay of cell lysate for intracellular ara-C/ara-CTP 
E. coli HA1 was prepared as described and diluted ten-fold into cell lysate. 
Triplicate 200 µL volumes were aseptically transferred to a 96 well black 
microtitre plate with IPTG (1 mM, Sigma-Aldrich, UK) and calf intestinal 
alkaline phosphatase (AP, Sigma-Aldrich, UK) (10 U per well) added as 
appropriate (to discriminate ara-CTP from ara-C), and incubated for 15 hours 
at 37°C in an Infinite® F200 Pro plate reader (Tecan, UK) with dynamic gain 
adjustment. Bioluminescence was monitored every 15 minutes. 
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Incubation of immortalised leukaemic cells with chemotherapeutic drugs for 
assessment of potentiation of ara-CTP generation 
Viable immortalised leukaemic cells (HL-60, KG-1a, K562 and THP-1) were 
enumerated using Trypan Blue staining and an Improved Neubauer 
haemocytometer, harvested by centrifugation at 300 x g for 5 minutes, and 
re-suspended to a density of 2 x 106 cells/mL in RPMI 1640 medium 
(unsupplemented, minus phenol red). Aliquots (2mL) were dosed with 
DMSO (0.1%, Fisher-Scientific, UK) as vehicle control or fludarabine (5 µM). 
Cells were incubated for 4 hours at 37°C in an atmosphere enriched with 5% 
CO2. Subsequently ara-C (10 or 25 µM), DNR (5 µM) or CPX-351 (10 or 25 
µM) were added and cells were incubated for a further 4 hours at 37°C in an 
atmosphere enriched with 5% CO2. Lysate was prepared and analysed for 
ara-CTP generation as described. 
Isolation, cryopreservation and thawing of primary AML cells 
Mononuclear cells were isolated from peripheral blood, collected with 
informed consent (07/H1109/181) from patients at Bristol Haematology and 
Oncology Centre (BHOC) by a density gradient technique following 
manufacturer’s instructions (Histopaque 1077, Sigma, UK). Peripheral blood 
mononuclear cells (PBMC) were cryopreserved at ≤3x107 cells/mL in RPMI 
1640 medium (with phenol red) containing FBS (25%), DMSO (5%) and L-
glutamine (2 mM). 
Cryopreserved PBMC (1 mL) were thawed in RPMI 1640 medium (with 
phenol red) containing FBS (50%) and L-glutamine (2 mM) (4 mL), pelleted 
at 300 x g for 5 minutes, and washed in RPMI 1640 medium (with phenol 
red) containing FBS (20%) and L-glutamine (2 mM) to remove traces of 
DMSO. Viability post-resuscitation was assessed by trypan blue enumeration 
with >80% required for further analysis. The cells were finally re-suspended 
in 10 mL RPMI 1640 medium (with phenol red) with FBS (20%) and L-
glutamine (2 mM) and incubated overnight at 37C in 5% CO2 before 
treatment with chemotherapeutic drugs fludarabine (5 µM) for 2 hours 
followed by CPX-351 (25 µM) for 1 hour. 
Cytotoxicity assessment 
Viable immortalised leukaemic cells (5×104 per well, 100 µL final volume) 
were cultured in the presence or absence of DNR (5 µM), cytarabine (25 µM) 
or CPX-351 (25 µM) with or without fludarabine (5 µM) for 24, 48 and 72 
hours and ATP generation by viable cells assessed by CellTiterGlo™ 
(Promega, UK). ATP levels were measured using an Infinite® F200Pro (Tecan, 
UK). Light units were used in the calculation of the viable mass (ATP%), with 
results expressed as percentage of treated over control. Results represent 
three separate experiments each performed in triplicate and are expressed 
as mean ±standard deviation (n = 3). 
Human equilibrative nucleoside transporter (hENT) inhibition 
Viable immortalised leukaemic cells (THP-1) were enumerated and cell 
number adjusted to 5x105/mL (5×104 per well). Cells were dosed with 
dipyridamole (DPM, Sigma-Aldrich, UK) (2 µM) or vehicle control (0.1% 
DMSO) for 2 hours followed with ara-C (25 µM) or CPX-351 (25 µM) and 
luminescence from ATP assessed by CellTiterGlo™ assay (Promega) at 24, 28 
and 72 hours (n=3). Results are expressed as %ATP treated/control. 
Statistical Analysis 
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Statistical analysis was undertaken where stated using GraphPad Prism 7 
software (GraphPad, CA, USA). Sensitivity Index (SI%) values from biosensor 
HA1 were calculated as described in Alloush et al. (2010). 
Results 
Intracellular ara-CTP from CPX-351 detected by biosensor HA1, is slower to 
generate but reaches comparable levels by 4 hours incubation with 
equivalent cytotoxic response as DA over 72 hours 
In vivo relevant and equivalent concentrations of ara-C and CPX-351 (25 µM) 
were assessed over 1-4 hours incubation with the HL-60 cell line (Fig. 1A), 
which we have previously shown to be highly sensitive to cytarabine 
(Anderson et al., 2013). Dosing with free (non-liposomal) ara-C produced an 
increase in bioluminescence (and hence ara-CTP) at each time-point tested 
consistent with previously published results (Anderson et al., 2013), 
achieving 169%, 318% and 497% SI% values at 1, 2 and 4 hours incubation 
respectively. Incubation of HL-60 cells with CPX-351 required a longer time-
period to result in similar levels of ara-CTP, but a dose-dependent increase 
was noted, with the highest increase (SI=274%) produced using 4-hour 
incubation of CPX-351 (25 µM). Assessment of intracellular ara-C and ara-
CTP following dosing with ara-C (Fig. 1C) showed significant generation of 
ara-CTP by 2 hours (p<0.001), however CPX-351 required 4 hours to achieve 
a similar level (Fig. 1D). Importantly, no significant difference in HL-60 
cytotoxicity was noted between ara-C and CPX-351 at any time-point tested 
(0-72 hours) (Fig. 1B) except for 48 hours where CPX-351 induced a further 
9% decrease in %ATP over ara-C (p<0.01). Additionally combined DA was 
compared with CPX-351 at each time-point and showed a significant 
decrease in cytotoxicity at 24 hours compared to both ara-C and CPX-351 
(p<0.001), however at 48 and 72 hours no significant difference in 
cytotoxicity was observed between ara-C and DA, or CPX-351 and DA 
(p>0.05). 
CPX-351 shows superior or equivalent toxic effects in HL-60, K562 and THP-1 
cell lines but not KG-1a 
To extend assessment of CPX-351 cytotoxicity, a panel of cell lines with 
varying sensitivity to cytarabine were tested with CPX-351 versus DA (Fig. 2). 
HL-60 cells showed the greatest sensitivity to DA after 72 hours incubation 
(viability versus control 7±0.5%) with equivalent cytotoxicity observed for 
CPX-351 (11±0.5%) at the same time-point (p>0.05) (Fig. 2A). However at 48 
hours CPX-351 showed superior cytotoxicity over DA (18±0.9% versus 
26±0.8%, p<0.05). K562 (erythroleukaemia) (Lozzio and Lozzio, 1975) and 
THP-1 cells (M5 AML) (Tsuchiya et al., 1980) represent two of the most 
cytarabine-resistant immortalised leukaemic lines available. For K562 cells, 
no significant decrease in viability was observable at any time-point 
examined for either DA or CPX-351 (Fig. 2C). The maximal cytotoxic effect 
was noted at 72 hours for DA and CPX-351 (90±2.4% versus 89±8.7%, 
p>0.05). For THP-1 cells, a significant increase in cytotoxic effect was noted 
for CPX-351 over DA at 48 hours (11±0.4% versus 38±1.8%, p<0.001) and 72 
hours (2±0.2% versus 16±0.6%, p<0.001) (Fig. 2D). KG-1a cells showed less 
susceptibility to DA and CPX-351 compared to HL-60 cells, and were the only 
cell line to show increased cytotoxicity in favour of DA at both 48 hours 
(51±2% versus 87±2.1%, p<0.001) and 72 hours (23±1.3% versus 58±2.6%, 
p<0.01) (Fig. 2B).  
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Intracellular concentration of ara-CTP from CPX-351 is not inhibited by hENT-
1 blockade in immortalised THP-1 leukaemic cells 
Fig. 3 shows the cytotoxicity of free ara-C versus CPX-351 on THP-1 cells at 
24, 48 and 72 hours in the presence and absence of DPM, an inhibitor of 
hENT1 and 2 (Wang et al., 2013). Ara-C (25 µM) incubation induced an 85% 
reduction in THP-1 cell viability at 72 hours that was nullified by 2 hour pre-
incubation with DPM (2 µM), confirming the requirement for hENT 
expression in the cytotoxicity of free ara-C. As expected given the rationale 
for liposomal packaging of DA in CPX-351, DPM had no significant effect on 
the cytotoxicity of CPX-351 (25 µM) at the same time-points tested (p>0.05), 
confirming that hENT transporters are not required for cytotoxicity of CPX-
351.  
Potentiation of ara-CTP from CPX-351 by pre-treatment with fludarabine is 
equivalent to cytarabine in immortalised leukaemic cell lines 
Following 4-hour incubation with fludarabine (5 µM) or DMSO control, cell 
suspensions (THP-1, HL-60 and K562) were exposed to DA or CPX-351 and 
incubated for 4 hours (Fig. 4), in line with optimised dosing results (Fig. 1A). 
For comparison the SI% values for CPX-351, Flu-CPX, DA and Flu-DA treated 
samples are included. Fig. 4 shows results from biosensor HA1 for THP-1 (Fig. 
4A), HL-60 (Fig. 4B) and K562 (Fig. 4C) cell lines dosed with DA, Flu-DA, CPX-
351 or Flu-CPX expressed as intracellular ara-CTP/ara-C ratios. DMSO was 
used as solvent for fludarabine and was controlled (0.1%) throughout 
alongside a fludarabine-only control (Fig. 4) and an untreated control (data 
not shown). Neither DMSO nor fludarabine control showed any increase in 
SI% over untreated control for any sample (ara-CTP/ara-C ratio of 1). 
In all cell lines an increase in ara-CTP accumulation was observed upon 
fludarabine pre-incubation, however Flu-DA produced a greater 
accumulation than Flu-CPX. No significant increase in ara-CTP/ara-C ratio 
was observed in THP-1 cells following four-hour incubation with DA or CPX-
351 versus control. However, potentiation of ara-CTP generation from CPX-
351 was observed in THP-1 cells (Fig. 4A) with an increase in ara-CTP/ara-C 
ratio with fludarabine pre-incubation from 0.96 to 1.24, indicating an 
intracellular shift from ara-C to ara-CTP (p=0.014). This translated into an 
increase in SI% from 0 to 42% with fludarabine pre-incubation. Similarly 
potentiation was observed for Flu-DA versus DA in this cell line, increasing 
the ara-CTP/ara-C ratio from 0.95 to 1.94 (p=0.0014), and the SI% from 14 
to 112%.  This represented the largest increase observed in the immortalised 
cell lines tested, in line with our previous findings for this cell line using 
biosensor HA1, and corroborated by HPLC (Anderson et al., 2013). In HL60 
cells, a trend towards potentiation was observed (Fig. 4C), with Flu-CPX 
increasing the ara-CTP/ara-C ratio from 1.11 to 1.36 (p=0.361) and the SI% 
from 25 to 50%. Flu-CPX induced a significant increase in ara-CTP/ara-C ratio 
over fludarabine only control (p=0.031). Comparison of DA to Flu-DA in this 
cell line (Fig. 4D) showed a similar increase in ara-CTP/ara-C ratio (1.33 to 
1.65, p=0.103) as observed for Flu-CPX, but a significant increase in ara-
CTP/ara-C ratio over fludarabine only control (p=0.0008). The effect of 
fludarabine pre-incubation was less pronounced in K562 cells (Fig. 4E & F) 
showing a trend towards increased SI% from 15 to 34% for CPX-351 
(p=0.283), and 73 to 86% for Flu-DA (p=0.888).  
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Fig. 5 shows viability of immortalised leukaemic cells lines following 
incubation with ara-C, FLA, CPX-351 or Flu-CPX over a 72-hour period. 
Fludarabine alone showed a slight but significant cytotoxic effect on HL-60 
(viability 70%) and K562 (viability 89%) cell lines, but not THP-1. HL-60 cells 
were the most sensitive of the cell lines to both ara-C (25 µM) as single 
agent, and combined FLA, with 7% and 6% viability over control at 72 hours, 
respectively. CPX-351 (25 µM) reduced HL-60 cell viability to 11% at 72 hours 
that decreased further to 6% viable with fludarabine co-incubation, 
confirming the trend observed in Fig. 4C. THP-1 cell viability decreased to 
15.8% after 72-hour incubation with ara-C, which did not decrease further 
with fludarabine incubation (14.8%) (Fig. 5B) despite a significant increase in 
ara-CTP generation (p<0.01, Fig. 4B). CPX-351 was again more cytotoxic to 
THP-1 cells than ara-C alone (p=0.0004) (also observed in Fig. 2D), which was 
most likely due to daunorubicin within CPX-351 liposomes, however Flu-CPX 
showed no further decrease in viability after 72 hours incubation (2.1% and 
2.4% respectively). K562 cells showed no significant decrease in viability 
when treated with ara-C or CPX-351 for 72 hours (90% and 89% 
respectively). The combination of fludarabine with ara-C and CPX-351 
reduced the viability to 84% (p=0.019) and 85% (p=0.042) respectively, 
however no significant difference was noted for either combination versus 
the effect of fludarabine alone, with fludarabine producing significant 
toxicity in this cell line (p<0.01). 
Flu-CPX potentiates generation of ara-CTP from CPX-351 in primary 
refractory AML blasts 
The patient cohort analysed were median age 68 years (range 66 to 72 years) 
and were analysed as presentation peripheral blood samples collected and 
cryopreserved within 24 hours of phlebotomy (Table S1). All samples were 
revived and analysed within 1 year of receipt due to our previous 
observation of loss of functionality with longer-term cryopreservation (data 
not shown). Optimisation of the dosing schedule in patient blasts for CPX-
351 was initially performed using material from patient ID04 since material 
was more plentiful for this patient. No detrimental effect on potentiation by 
fludarabine was observed by reducing the pre-incubation from 4 hours to 2 
hours, nor the subsequent CPX-351 incubation to 1 hour (data not shown). 
Patient ID01 was diagnosed with FLT3- AML with monosomy 7 and due to 
poor fitness scores was treated with 1 cycle of low-dose ara-C but 
subsequently showed rising white cell count and died. Fig. 6 indicates that 
patient ID01 would have produced little ara-CTP from CPX-351 (SI=0.4%), 
however fludarabine pre-treatment induced a 19% improvement in SI% for 
this patient (p<0.001). Patient ID02 had AML with normal karyotype that was 
treated with DA 3+10 but who died 8 days after completing course 1. A 
similar trend in response was noted as for ID01 although this was not 
significant, with ID02 showing low conversion of ara-C to ara-CTP from CPX-
351 (SI=4.6%) that was improved with fludarabine pre-treatment to 10.1% 
(p>0.05). 
Patient ID03 was diagnosed with NPM1+/FLT3+ AML (normal cytogenetics) 
and received DA 3+10 (at 50% dose) and was refractory, followed by two 
cycles of FLAG-Ida showing residual disease, followed by palliation. This 
patient showed the ability to generate ara-CTP from CPX-351 (SI=9.5%) that 
was improved by fludarabine pre-treatment to 26.1% (p<0.001) (Fig. 6). 
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Patient ID04 had NPM1-/FLT3+ AML (normal cytogenetics) and received two 
cycles of DA (3+10 then 3+8) but was refractory, then received and was 
refractory to FLAG-Ida.  This patient showed an improvement from 9.4% to 
21.7% for Flu-CPX over CPX-351 alone. Patient ID05 was diagnosed with 
NPM1-/FLT3+ M1 AML and received DA 3+10 with Mylotarg followed by 
FLAG-Ida but was refractory to all. Fig. 6 indicates that this patient’s blasts 
showed the highest response to CPX-351 of the cohort tested, and Flu-CPX 
improved ara-CTP generation from CPX-351 in this patient’s sample, 
increasing the SI% from 12.4% to 21.6% (p<0.001).  
Discussion 
Initial analysis of uptake and metabolism of CPX-351 in the cytarabine-
sensitive cell line HL-60 identified an approximate 2-hour lag in ara-CTP 
generation for CPX-351 compared to DA molar equivalents (Fig. 1A). This 
delay in intracellular formation of ara-CTP was consistent with prior 
observations whereby CPX-351 liposomes are taken up intact by leukaemia 
cells in an energy-dependent process, requiring intracellular processing of 
the liposomes to release the encapsulated drugs, which subsequently can 
interact with their nuclear targets (Kim et al., 2011; Lim et al., 2010). 
Biosensor E. coli HA1 is able to monitor both ara-C and ara-CTP by measuring 
signals in the absence and presence of AP, respectively. Interestingly, a time-
dependent increase in the ratio of ara-CTP/ara-C could be noted across the 
three time-points tested for CPX-351 (0-4 hours post-dosing), whereas when 
the free drug ara-C was incubated with HL-60 cells the predominant species 
at all time-points was ara-CTP (Fig. 1C & D). This indicates that the lag could 
be caused prior to dCK mono-phosphorylation of ara-C, and most likely is 
due to intracellular release of ara-C from the liposome during the first hour 
of incubation (Fig. 1A). Of key importance was the observation that 
cytotoxicity of CPX-351 reached equivalence to cytarabine in HL-60 cells by 
24 hours, and DA by 48 hours incubation (Fig. 1B). Further investigation of 
the intracellular ara-C and DNR handling from CPX-351 over the initial 24 
hours post-treatment is required to elucidate the intracellular kinetics. 
To compare efficacy of DA versus CPX-351 further, a range of commercially 
available leukaemic cell lines were incubated with molar equivalents of CPX-
351 and ara-C, and viability was assessed (Fig. 2). The cell lines selected 
represent a range of sensitivities to cytarabine, from highly sensitive (HL-60, 
KG-1a) to resistant (K562, THP-1) (Anderson et al., 2013). HL-60 and THP-1 
cells showed increased susceptibility to CPX-351-induced cytotoxicity 
compared to DA at 48 hours. This cytotoxic effect reached equivalence for 
HL-60 cells at 72 hours (Fig. 2A), however for the more resistant cell line THP-
1, a sustained superior effect of CPX-351 was observable at 72 hours (Fig. 
2D). K562 cells were found to be the most resistant cell line tested, with 
neither DA nor CPX-351 inducing a significant cytotoxic effect (Fig. 2C). K562 
cells have been shown to respond to tetrahydrouridine-induced inhibition of 
cytidine deaminase (CDA), inducing a two-fold increase in ara-CTP 
accumulation (Riva et al., 1992), which may provide a possible mechanism 
for their relative insensitivity to cytarabine and CPX-351.  This cell line may 
be suitable for testing of high-dose equivalents for CPX-351 versus 
cytarabine, mirroring relapse regimen equivalents of ara-C (1.5-3g/m2). KG-
1a was the only cell line to show superior cytotoxic effect of DA over CPX-
351 (Fig. 2B). KG-1a cells are derived from a male patient with M0 AML 
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(Koeffler, 1983) and are known to express leukaemic stem cell-like (LSC) 
properties (CD34+CD38-) rendering them resistant to anthracycline-based 
chemotherapy (She et al., 2012). This cell line may be a useful tool for further 
investigation of CPX-351 efficacy in LSC populations and warrants further 
investigation.  
Nucleoside analogues such as fludarabine and cytarabine require active 
uptake via hENT that accounts for 80% of influx into the cell (Sundaram et 
al., 2001). Loss of hENT1 is known to induce cytarabine resistance and 
shorter survival in vivo (Cai et al., 2008; Galmarini et al., 2002). The role of 
hENT-1 in the cytotoxicity of ara-C from CPX-351 versus free ara-C was 
assessed to illustrate the importance of liposomal uptake independent of 
hENT-1 transport. One proposed mechanism of cytarabine resistance 
thought to affect response to AML therapy is low-level expression of hENT1. 
A study evaluating cytarabine resistance mechanisms in 26 AML patients 
failed to identify a correlation between hENT1 and ara-CTP generation 
(Yamauchi et al., 2009). However, no study has evaluated hENT1 expression 
versus outcome of therapy in AML, but a notable correlation has been 
observed between hENT1 expression and response to the related compound 
gemcitabine in patients with resected gastric cancer (Santini et al., 2010). 
In this study, hENT-inhibition was assessed using DPM, an inhibitor of hENT1 
and 2 (Wang et al., 2013). DPM pre-incubation successfully inhibited 
cytarabine-induced cytotoxicity in THP-1 cells at 48 and 72 hours (p<0.001), 
however cytotoxicity of CPX-351 was unaffected by hENT blockade (p>0.05) 
(Fig. 3). It should be noted however that whilst cytarabine requires hENT1 
for uptake into cells, fludarabine requires hENT2 and thus any reduction in 
hENT2 expression could affect the efficacy of Flu-CPX as is known for the use 
of fludarabine in chronic lymphocytic leukaemia (CLL) (Molina-Arcas et al., 
2005). DPM would be a suitable inhibitor to test this effect further in a range 
of cell lines and patient blasts as it is known to inhibit both hENT1 and hENT2, 
and could be compared with a hENT1-specific inhibitor such as 
nitrobenzylthioinosine (NBMPR) (Boleti et al., 1997). 
Following optimisation of in vitro exposure to CPX-351, potentiation of ara-
CTP generation was assessed using biosensor HA1 (Alloush et al., 2010) 
following 4-hour incubation with fludarabine (5 µM), a concentration 
previously shown to increase ara-CTP accumulation in vivo (Gandhi et al., 
1993) and in susceptible cell lines (Anderson et al., 2013). Cytotoxicity of the 
combinations was assessed over a further 72 hours (Fig. 5). Bioluminescence 
from biosensor HA1 was used to assess both ara-CTP and ara-C (Alloush et 
al., 2010). For ease of comparison the ara-CTP/ara-C ratio was calculated for 
each treatment, with a ratio >1 indicating the intracellular predominance of 
the active metabolite ara-CTP, and <1 indicating ara-C as the predominant 
form of the drug. Flu-CPX was assessed versus Flu-DA to control for the 
presence of DNR within CPX-351 liposomes, despite Flu-DA not being used 
clinically. Comparison of Flu-DA versus FLA (fludarabine 5 µM and ara-C 25 
µM) showed no significant difference in SI% from biosensor HA1, indicating 
that the presence of DNR did not impact on ara-CTP generation (data not 
shown). Clinically, high-dose cytarabine is used at relapse. However, due to 
previously observed saturation of ara-CTP accumulation in cell lines 
(Anderson et al., 2013), and following in vivo high-dose cytarabine 1-2 hours 
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post-administration (Plunkett et al., 1987), standard-dose DA equivalents 
were tested herein. 
Potentiation of ara-CTP from CPX-351 by fludarabine pre-treatment was 
most pronounced in THP-1 cells (Fig. 4A), causing a significant shift in 
conversion to ara-CTP versus CPX-351 as single agent (p<0.05). Interestingly, 
potentiation of ara-CTP generation after treatment with Flu-DA was also 
notable in THP-1 cells (p<0.01) (Fig. 4B), however cytotoxicity was 
substantially higher for CPX-351 versus ara-C, and importantly Flu-CPX 
versus FLA at both 48 and 72 hours post-dosing (Fig. 5B). In contrast, THP-1 
cells showed no significant increase in ara-CTP accumulation following four-
hour incubation with CPX-351 or DA without fludarabine versus control (Fig. 
4A & B), despite significant cytotoxicity by ara-C and CPX-351 from 24 and 
48 hours respectively. Reduced sensitivity to ara-C through decreased ara-
CTP generation have been observed previously in this cell line (Anderson et 
al., 2013; Ge et al., 2004) and is attributable to increased CDA function (Ge 
et al., 2004). As the cytotoxicity of ara-C is not restricted to formation of ara-
CTP, other mechanisms such as induction of apoptosis through membrane 
raft-induced ceramide formation (Grazide et al., 2002) mitochondrial 
swelling (Xue et al., 2002), and NF-B down-regulation (Sreenivasan et al., 
2003) may be active in this cell line. This phenomenon warrants further 
investigation to determine whether this lack of concordance between ara-
CTP accumulation at 4 hours and 72 hour cytotoxicity is due to the previously 
observed altered kinetics of CPX-351 versus standard DA (Lim et al., 2010), 
or direct toxicity from parent ara-C formed from CPX-351. 
No significant shift in ara-CTP/ara-C ratio was observable for either HL-60 or 
K562 cells treated with Flu-CPX versus CPX-351 alone (Fig. 4C & E 
respectively), however the same was also true for Flu-DA versus DA (Fig. 4D 
& F respectively). HL-60 are known to be highly sensitive to cytarabine-based 
chemotherapy, with IC50 values of 200-350 nM (Anderson et al., 2013; 
Yamauchi et al., 2014). Due to the high sensitivity of this cell line to ara-C 
(Anderson et al., 2013, Yamauchi et al., 2014), no significant reduction in 
viability was noted with fludarabine potentiation (Fig. 5A), mirroring the 
finding that no significant difference in ara-CTP generation was observed 
after fludarabine pre-treatment (Fig. 4D). K562 cells were resistant to both 
ara-C and CPX-351 during the initial 72 hours post-dosing, with fludarabine 
potentiation of either CPX-351 or ara-C showing no further cytotoxic effect 
over fludarabine alone (p>0.05) (Fig. 5C). With K562 anthracycline-resistant 
phenotypes having been developed and investigated (Damiano et al., 2001; 
Peng et al., 2011), this cell line may be useful in modelling intracellular 
handling of CPX-351 in resistant disease. 
Following observation of increased ara-CTP accumulation and cytotoxicity of 
Flu-CPX in immortalised cell lines, the combination was tested in ex vivo 
blasts from a cohort of presentation AML patient samples (n=5). All patients 
were subsequently refractory to frontline chemotherapy with DA or low-
dose ara-C (ID01), and 3/5 had subsequently failed to respond to FLAG-Ida 
(ID03, ID04, ID05) (Fig. 6). Flu-CPX induced a significant increase in 
accumulation of ara-CTP over CPX-351 alone in 4/5 patient samples tested. 
The most extensive improvement in ara-CTP accumulation from Flu-CPX was 
observable for patient ID01, who suffered poor fitness scores and was 
treated with low-dose cytarabine. This predicted improvement indicates 
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that patient ID01 could potentially have benefited from the combination 
given the improved tolerability reported previously for CPX-351 (Lancet et 
al., 2014). Three patients with mutations in FLT3-ITD were analysed as part 
of the cohort. CPX-351 has previously shown favourable response in AML 
blasts harbouring the FLT3-ITD mutation, due to increased uptake and 
cytotoxic effect (Gordon et al., 2017). A significant potentiation of ara-CTP 
was observable in blasts from all 3/3 FLT3-ITD positive patients analysed 
(p<0.01) (ID03, ID04 and ID05), and this fludarabine-mediated potentiation 
of ara-CTP from CPX-351 may indicate a rationale for this combination in 
FLT3-ITD positive disease. 
This study has demonstrated the ability of fludarabine to potentiate 
formation of ara-CTP upon exposure of immortalised (THP-1) and primary 
leukaemia cells to CPX-351, suggesting a favourable impact on efficacy for 
this combination. Interestingly, CPX-351 appeared to circumvent the impact 
of hENT1 inhibition on cytotoxicity in immortalised leukaemia cells, and 
showed a greater propensity for fludarabine to potentiate ara-CTP 
generation from CPX-351 in patient blasts, despite the cohort showing lower 
basal sensitivity to CPX-351 compared to the cell lines tested. Biosensor HA1 
is able to detect intracellular ara-CTP from CPX-351 and should be evaluated 
further in a larger cohort of patient samples with known outcome, for use as 
a treatment decision-making tool. Flu-CPX is being examined in the current 
UK NCRI AML19 Trial. Further studies are required to elucidate intracellular 
drug handling of CPX-351, and evaluate cytotoxicity and intracellular ara-CTP 
and DNR accumulation from CPX-351 in models of resistant AML. 
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Figure Captions 
 
Fig. 1: Generation of ara-CTP from free drug ara-C and CPX-351 (A) and 
viability of CPX-351 versus free ara-C and DA on HL-60 cells after 0-72 hour 
incubation (B), and kinetics of ara-C conversion to ara-CTP for ara-C-
treated (C) and CPX-351-treated (D) HL-60 cells. (A) Sensitivity Index (SI%) 
from biosensor HA1 incubated with lysate from HL-60 cells either untreated, 
or treated with DA (DNR 5 µM, ara-C 25 µM) or CPX-352 (25 µM) for 1 hour, 
2 hours or 4 hours. (B) HL-60 cells seeded at 5x105/mL were dosed with DA 
(5 µM and ara-C 25 µM), CPX-351 (25 µM) or DA (5 µM DNR and 25 µM ara-
C) and luminescence from ATP assessed by CellTiterGlo™ assay (Promega) at 
24, 28 and 72 hours. Raw relative light unit (RLU) values are indicated above 
controls. Intracellular ara-C & ara-CTP levels for HL-60 cells treated with (C) 
ara-C (25 µM) or (D) CPX-351 (25 µM) assessed as relative light units from 
biosensor HA1. Significance calculated for each species at each time-point. 
SI% values calculated as per Alloush et al. (2010). CellTiterGlo™ results are 
expressed as %ATP treated/control. RLU, relative light units; AP, alkaline 
phosphatase. Error bars represent standard deviation (n=3) with one-way 
ANOVA with Tukey’s post-hoc test, ns, not significant, **p<0.01, 
***p<0.001. 
 
Figr-2 
Fig. 2: Cytotoxicity of CPX-351 versus DA on (A) HL-60, (B) KG-1a, (C) K562 
and (D) THP-1 cells after 24, 48 and 72 hours incubation. Leukaemic cells 
seeded at 5x105/mL were dosed with ara-C (25 µM) or CPX-351 (25 µM) and 
luminescence from ATP assessed by CellTiterGlo™ assay (Promega) at 24, 28 
and 72 hours. Results are expressed as %ATP treated/control with raw 
relative light unit (RLU) values indicated above controls. Error bars represent 
standard deviation (n=3) with one-way ANOVA with Tukey’s post-hoc test, 
ns, not significant, *p<0.05, **p<0.01, ***p<0.001. 
 
Figr-3 
Fig. 3: Effect of hENT inhibition on cytotoxicity of CPX-351 versus free ara-
C on THP-1 cells after 24, 48 and 72 hours incubation. THP-1 cells seeded at 
5x105/mL were dosed in the presence and absence of DPM pre-treatment 
for 2 hours (2 M) with ara-C (25 µM) or CPX-351 (25 µM) and luminescence 
from ATP assessed by CellTiterGlo™ assay (Promega) at 24, 28 and 72 hours. 
Results are expressed as %ATP treated/control. Error bars represent 
standard deviation (n=3) with one-way ANOVA with Tukey’s post-hoc test, 
ns, not significant; **p<0.01; ***p<0.001. 
 
Figr-4 
Fig. 4: Effect of fludarabine pre-treatment on potentiation of ara-CTP from 
CPX-351 in leukaemic cell lines (THP-1, HL-60 and K562). Cells (2x106/mL) 
were treated vehicle control (DMSO 0.1% v/v) or fludarabine (5 µM) for 4 
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hours and then CPX-351 (25 µM) or DA (DNR 5 µM and ara-C 25 µM) for 4 
hours and lysates produced and analysed as per Anderson et al. (2013). 
Three experimental repeats are shown (n = 3) ± SD. One-way ANOVA with 
Tukey’s post-hoc test was performed versus appropriate control (i.e. Flu-CPX 
versus fludarabine), with bars indicating comparison ± fludarabine pre-
treatment (i.e. Flu-CPX versus CPX-351). ns, not significant, *p<0.05, 
**p<0.01, ***p<0.001. Flu, fludarabine; FLA, fludarabine plus ara-C. 
 
Figr-5 
Fig. 5: Cytotoxicity of combined Flu-CPX versus FLA on (A) HL60, (B) THP-1 
and (C) K562 cells after 24, 48 and 72 hours incubation. Immortalised 
leukaemic cells seeded at 5x105/mL were dosed with vehicle control (0.1% 
v/v DMSO), fludarabine (5µM), ara-C (25 µM), FLA (fludarabine at 5µM and 
ara-C at 25 µM), CPX-351 (25 µM) or Flu-CPX (fludarabine at 5µM and CPX-
351 at 25 µM) and luminescence from ATP assessed by CellTiterGlo™ assay 
(Promega) at 24, 28 and 72 hours. Results are expressed as log10 %ATP 
treated/control, with raw relative light unit (RLU) values indicated above 
controls. Error bars represent standard deviation (n=3) with one-way 
ANOVA with Sidak’s post-hoc test, ns, not significant, *p<0.05, **p<0.01, 
***p<0.001. 
 
Figr-6 
Fig. 6: Effect of fludarabine pre-treatment on potentiation of ara-CTP from 
CPX-351 in primary refractory AML blasts. Peak luminescence from 
biosensor HA1 incubated with lysate prepared from cryopreserved (<1 year) 
peripheral blood mononuclear extract from presentation AML patients that 
failed to achieve remission on standard induction and relapse regimens. 
Cells were treated for 2 hours with vehicle control (0.1% DMSO v/v) or 
fludarabine (5 µM) followed by 1 hour incubation with CPX-351 (25 µM). 
Error bars represent standard deviation (n=3). AP, alkaline phosphatase, SI%, 
sensitivity Index (SI%) values calculated as per Alloush et al. (2010). One-way 
ANOVA with Tukey’s post-hoc test: ns, not significant; **p<0.01; 
***p<0.001. 
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